Sarepta Therapeutics | Biopharmaceutical Company for Rare …
Sarepta is a global biotechnology company on an urgent mission: engineer precision genetic medicine to reclaim futures otherwise impacted or cut short by rare diseases.
Sarepta Therapeutics, Inc. (SRPT) - Yahoo Finance
Find the latest Sarepta Therapeutics, Inc. (SRPT) stock quote, history, news and other vital information to help you with your stock trading and investing.
Sarepta - Wikipedia
Sarepta (near modern Sarafand, Lebanon) was a Phoenician city on the Mediterranean coast between Sidon and Tyre, also known biblically as Zarephath. It became a bishopric, which faded, and remains a double (Latin and Maronite) Catholic titular see.
Sarepta Therapeutics - Wikipedia
Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States.
About Our Company - Sarepta Therapeutics
Sarepta is a global biotechnology company on an urgent mission: to engineer precision genetic medicine for rare diseases that devastate lives and cut futures short.
Sarepta — Wikipédia
Sarepta était une ville phénicienne fortifiée sur la côte méditerranéenne entre Sidon et Tyr, à proximité de l’actuelle ville libanaise de Sarafand, qui conserve le nom de la cité antique.
Our Pipeline | Sarepta Therapeutics
Jun 27, 2024 · Sarepta’s industry leading pipeline is comprised of over 40 programs in various stages of development across 3 technologies, RNA, gene therapy and gene editing, and multiple therapeutic areas including neuromuscular, CNS and cardiology.
In a first, FDA approves Sarepta gene therapy for Duchenne …
Jun 22, 2023 · Sarepta's muscular dystrophy treatment is the first gene therapy approved under the program. The disease, which almost exclusively affects boys, destroys muscles.
Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the …
Jun 22, 2023 · Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development.
Sarepta Therapeutics Announces Expanded US FDA Approval of …
Jun 20, 2024 · Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development.